The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Manuel Pérez‐Encinas et al.|Blood|2023Cited by 15
Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed <i>FLT3</i>-ITD Negative AMLPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Blood|2024Cited by 5
Lack of p38 activation in T cells increases IL-35 and protects against obesity by promoting thermogenesisIvana Nikolić, Guadalupe Sabio, Pilar Martı́n et al.|EMBO Reports|2024Cited by 4
Enhanced Validation of the <i>FLT3</i>-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in <i>FLT3-ITD</i> Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Manuel Pérez‐Encinas et al.|Blood|2024Cited by 3
Molecular Mechanisms of Quizartinib Response in <i>FLT3-ITD</i> Negative AML: An Updated Analysis from the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Manuel Pérez‐Encinas et al.|Blood|2024Cited by 1